HomeCompareTSBX vs ORCC

TSBX vs ORCC: Dividend Comparison 2026

TSBX yields 563.38% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TSBX wins by $156404.03M in total portfolio value
10 years
TSBX
TSBX
● Live price
563.38%
Share price
$0.36
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$156404.05M
Annual income
$115,926,179,183.70
Full TSBX calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — TSBX vs ORCC

📍 TSBX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTSBXORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TSBX + ORCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TSBX pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TSBX
Annual income on $10K today (after 15% tax)
$47,887.32/yr
After 10yr DRIP, annual income (after tax)
$98,537,252,306.14/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, TSBX beats the other by $98,537,252,305.26/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TSBX + ORCC for your $10,000?

TSBX: 50%ORCC: 50%
100% ORCC50/50100% TSBX
Portfolio after 10yr
$78202.04M
Annual income
$57,963,089,592.37/yr
Blended yield
74.12%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

TSBX
No analyst data
Price Target
$0.50
+40.8% upside vs current
Range: $0.50 — $0.50
Altman Z
-23.2
Piotroski
2/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TSBX buys
0
ORCC buys
0
No recent congressional trades found for TSBX or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTSBXORCC
Forward yield563.38%9.79%
Annual dividend / share$2.00$1.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$156404.05M$21.4K
Annual income after 10y$115,926,179,183.70$1.04
Total dividends collected$152979.84M$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst price target$0.50$16.00

Year-by-year: TSBX vs ORCC ($10,000, DRIP)

YearTSBX PortfolioTSBX Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$67,038$56,338.03$11,190$489.61+$55.8KTSBX
2$424,702$352,971.06$12,229$256.01+$412.5KTSBX
3$2,544,295$2,089,864.53$13,216$130.74+$2.53MTSBX
4$14,423,258$11,700,861.61$14,207$66.02+$14.41MTSBX
5$77,424,065$61,991,178.81$15,234$33.17+$77.41MTSBX
6$393,842,555$310,998,805.50$16,317$16.62+$393.83MTSBX
7$1,899,912,512$1,478,500,978.24$17,468$8.32+$1899.90MTSBX
8$8,698,653,014$6,665,746,626.53$18,695$4.16+$8698.63MTSBX
9$37,829,785,494$28,522,226,769.44$20,006$2.08+$37829.77MTSBX
10$156,404,049,663$115,926,179,183.70$21,407$1.04+$156404.03MTSBX

TSBX vs ORCC: Complete Analysis 2026

TSBXStock

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.

Full TSBX Calculator →

ORCCBDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this TSBX vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TSBX vs SCHDTSBX vs JEPITSBX vs OTSBX vs KOTSBX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.